ReviewCurrent medical science2026
Glucose Metabolic Reprogramming in Thyroid Cancer: Underlying Molecular Mechanisms and Links to Progression and Treatment.
Review in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Thyroid cancer (TC) is a common endocrine malignancy with rapidly increasing global incidence. Clinical management remains challenging for advanced and radioiodine-refractory thyroid cancer (RAIR-TC). Metabolic reprogramming, especially enhanced aerobic glycolysis (the Warburg effect), is a core hallmark of TC that drives tumor progression and therapeutic resistance. This review systematically summarizes the molecular mechanisms of glucose metabolic reprogramming in TC, focusing on key oncogenic drivers including BRAF V600E mutation, RAS mutation, and RET/PTC rearrangement, as well as their downstream mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathways. These pathways coordinately upregulate critical glycolytic regulators: glucose transporter 1 (GLUT1), hexokinase 2 (HK2), pyruvate kinase M2 (PKM2), and lactate dehydrogenase A (LDHA). We further discuss emerging therapeutic strategies targeting glucose metabolism and highlight challenges including isoform-specific regulation and biomarker-driven patient stratification. This review provides a conceptual framework for translating metabolic insights into improved diagnosis and therapy for TC.
Indexed as
Identifiers
42126497What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.